Greenbrook TMS Inc is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy for patients suffering from treatment-resistant depression and other mental health disorders. The company's corporate philosophy revolves around a commitment to patients' well-being, providing innovative and effective treatment options. Greenbrook TMS Inc values patient-centric care, aiming to improve their quality of life by offering safe, non-invasive, and evidence-based TMS therapy. By prioritizing clinical excellence, collaboration, and continuous improvement, Greenbrook TMS Inc strives to be at the forefront of advancing mental health treatment. Through their dedication to research and investing in cutting-edge technology, Greenbrook TMS Inc continues to make a positive impact on individuals struggling with mental health challenges.

Greenbrook TMS Inc is primarily present in Canada and the United States.

Greenbrook TMS Inc has achieved several significant milestones. One of the noteworthy achievements for the company was its initial public offering (IPO) in July 2019. This milestone allowed Greenbrook TMS Inc to increase its capital and expand its operations. Additionally, the company has made significant progress in increasing its market presence by opening new treatment centers across North America. Furthermore, Greenbrook TMS Inc has attained widespread recognition for its innovative Transcranial Magnetic Stimulation (TMS) therapy, positioning itself as a leader in the mental health treatment industry. These achievements demonstrate the company's commitment to growth and improving mental health outcomes for patients.

Greenbrook TMS Inc is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy for patients with treatment-resistant mental health disorders in the United States and Canada. Founded in 2011, the company has quickly established itself as a trusted name in the field of neuromodulation therapy. Greenbrook TMS offers a non-invasive treatment option for individuals suffering from depression and obsessive-compulsive disorder (OCD) who have not responded well to traditional interventions. With a network of experienced clinicians and state-of-the-art TMS technology, Greenbrook TMS Inc continues to make significant advancements in the mental health industry, providing hope and improved outcomes for patients across North America.

The main competitors of Greenbrook TMS Inc in the market include companies such as Neuronetics Inc, Magstim, Brainsway Ltd, and NeuroStar Advanced Therapy.

Greenbrook TMS Inc is primarily active in the healthcare industry.

The business model of Greenbrook TMS Inc focuses on providing Transcranial Magnetic Stimulation (TMS) therapy for patients suffering from treatment-resistant depression (TRD) and other mental health disorders. Greenbrook TMS Inc operates a network of outpatient clinics where certified healthcare professionals administer TMS therapy using advanced medical technologies. By delivering non-invasive and drug-free treatment options, Greenbrook TMS Inc aims to improve the quality of life for individuals struggling with mental health conditions.

Коефициентът на цена спрямо печалбата (КЦП) на Greenbrook Tms е -0,02.

Коефициентът на цена към оборот (KUV) на Greenbrook Tms е 0,00.

AlleAktien качественият резултат за Greenbrook Tms е 5/10.

очаквана Greenbrook Tms оборотът е 92,08 млн. USD.

очаквана Greenbrook Tms печалба е -15,75 млн. USD.

Greenbrook TMS Inc. is a Canadian company specialized in the treatment of mental illnesses using transcranial magnetic stimulation (TMS). The company was founded in 2007 and is based in Toronto, Canada. Greenbrook TMS is listed on the Toronto Stock Exchange and has numerous offices in Canada and the USA. Greenbrook TMS offers innovative and clinically proven solutions for mental illnesses such as depression, anxiety disorders, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD). TMS, which is the focus of all treatment approaches, provides a safe and gentle alternative to conventional medication-based treatment. Greenbrook TMS has three business divisions: clinical services, device sales, and research and development. Clinical services are provided in the USA and Canada and include the treatment of patients in clinics, hospitals, and outpatient practices. Greenbrook TMS provides comprehensive TMS treatment to its customers, including pre-evaluations, individual treatment plans, and post-treatment care. Device sales involve the sale of TMS devices to medical facilities, psychiatrists, and psychologists. Greenbrook TMS offers a wide range of TMS devices tailored to the specific needs of their practice or clinic. The devices are installed and maintained by experienced technicians to ensure they are safe and effective at all times. The research and development division focuses on developing new TMS applications and conducting clinical studies. Greenbrook TMS is dedicated to constantly improving its TMS technology and developing new applications to treat a broader range of mental illnesses. The company also operates its own research department that focuses on the relationship between TMS and brain functions. Over the years, Greenbrook TMS has developed a wide range of products and services tailored to the specific needs of customers in various industries. Key products by Greenbrook TMS include the Brainsway Deep TMS devices designed for the treatment of depression, anxiety disorders, and OCD. The company also offers a wide range of TMS coils suitable for various applications and anatomies. Greenbrook TMS has established itself as a market leader in the TMS industry and is committed to advancing TMS technology and improving the quality of life for people with mental illnesses. The company works closely with medical professionals and innovators to develop the best TMS technology and clinical procedures.

Greenbrook Tms разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Greenbrook Tms в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Greenbrook Tms е CA3937043097.

WKN на Greenbrook Tms е A2QQKR.

Тикерът на Greenbrook Tms е GBNHF.

През последните 12 месеца Greenbrook Tms изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Greenbrook Tms да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Greenbrook Tms в момента е .

Greenbrook Tms изплаща дивидент на тримесечие. Той се разпределя в месеците .

Greenbrook Tms платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Greenbrook Tms се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Greenbrook Tms на 26.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 26.09.2024 г..

Последното дивидентно плащане беше извършено на 26.09.2024 г..

През година 2023 Greenbrook Tms изплати 0 USD под формата на дивиденти.

Дивидентите от Greenbrook Tms се изплащат в USD.